Immutep Limited
NASDAQ:IMMPBiotechnology
Healthcare
$0.37 +0.64%
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
52W Low $0.29High $3.53
Volume 3.10M
Average 13.46M
Income Statement
Follow revenue through to earnings.
Revenue
$5.04M
FY 2025 · Annual
+31.3% YoYOperating Income
-$126.42M
FY 2025 · Annual
Net Income
-$61.43M
FY 2025 · Annual
Income Statement
AUD
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 3.86M | 170.37K | 3.51M | 3.84M | 5.04M |
| Cost of Revenue | 17.24M | 2.06M | 2.06M | 41.55M | 61.41M |
| Gross Profit | (13.37M) | (1.89M) | 1.44M | (37.7M) | (56.37M) |
| Gross Margin | -346.2% | -1111.2% | 41.2% | -981.4% | -1117.6% |
| Research & Development | 17.24M | 31.34M | 28.79M | 41.55M | 61.41M |
| Selling, General & Admin | 6.28M | 7.21M | 14.08M | 8.85M | 8.64M |
| Operating Expenses | 18.3M | 32.55M | 44.94M | 50.4M | 70.06M |
| Depreciation & Amortization | 1.89M | 1.84M | 1.86M | 2.01M | 2.13M |
| EBITDA | (17.77M) | (31.87M) | (39.57M) | (44.54M) | (62.88M) |
| EBITDA Margin | -460.0% | -18708.9% | -1128.8% | -1159.4% | -1246.6% |
| Operating Income | (31.68M) | (33.94M) | (77.69M) | (88.1M) | (126.42M) |
| Operating Margin | -820.0% | -19920.0% | -2216.0% | -2293.3% | -2506.5% |
| Interest Income | 105.33K | 224.52K | 939K | 3.88M | 5.25M |
| Interest Expense | 9.83K | 92.43K | 20.4K | 30.59K | 24.01K |
| Other Income / Expenses | 1.77M | 1.63M | 37.79M | 45.39M | 64.99M |
| Income Before Tax | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Pre-Tax Margin | -774.1% | -18906.5% | -1138.0% | -1111.9% | -1218.0% |
| Income Tax Expense | 33 | 34 | 0 | 0 | 0 |
| Net Income | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Net Margin | -774.1% | -18906.5% | -1138.0% | -1111.9% | -1218.0% |
| EPS (Basic) | (0.49) | (0.37) | (0.44) | (0.36) | (0.42) |
| EPS (Diluted) | (0.49) | (0.37) | (0.44) | (0.36) | (0.42) |
| 60.43M | 86.23M | 90.06M | 119.99M | 145.58M | |
| 60.43M | 86.23M | 90.06M | 120.11M | 145.58M |
IMMP Earnings Waterfall · TTM
NASDAQ:IMMP · Revenue to Net Income
Key Ratios
EPS$-0.90
Gross Margin-1075.2%
Net Margin-1189.1%
P/E Ratio-3.9
P/S Ratio167.4
Analysis
$12.8M of revenue converted into -$127.8M of net income for the selected period. Gross margin is -1075.2% and net margin is -1189.1%, showing how much revenue survives after costs and taxes. EPS is $-0.90, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Sep 11, 2026 | |
| 6-K | 6-K filing | Sep 2, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 6-K | 6-K filing | Jul 14, 2026 | |
| 6-K | 6-K filing | Jun 5, 2026 |
How much revenue does IMMP generate?
Immutep Limited (IMMP) reported $5.04M of revenue in fiscal 2025.
Is IMMP profitable?
Immutep Limited (IMMP) reported -$61.43M of net income, with a net margin of -1218.0%.
Continue the stock analysis
Jump to another research area for this company.